Now I have all the evidence I need. Let me produce the consolidated review.

---

## Summary

This paper presents **YAIB (Yet Another ICU Benchmark)**, a modular, extensible framework for reproducible clinical ML experiments on ICU data. It natively supports five major open-access ICU datasets (MIMIC-III/IV, eICU, HiRID, AUMC) and provides end-to-end pipelines from cohort definition through model evaluation. The authors provide baseline results for six model architectures across five clinical prediction tasks and four datasets, and demonstrate how seemingly arbitrary design choices (cohort criteria, feature sets, label definitions) can shift performance more than model architecture.

---

## Strengths

- **Unique multi-dataset interoperability.** YAIB is the only ICU benchmark supporting all five major open-access datasets (Table 1), enabling cross-dataset comparison and transfer learning that prior single-dataset benchmarks cannot provide.

- **Extensibility by design.** The framework's modular architecture (Section 3.1) separates cohort definition, preprocessing, models, and tasks into independent, swappable components. Users can add new datasets, tasks, or models without rewriting core code — a genuine improvement over hardcoded pipelines like the HiRID benchmark or MIMIC-Extract.

- **Empirically demonstrates that cohort/definition choices often matter more than model architecture.** The cohort-leakage experiment (Table 3: 2–3 point AUROC shift from changing the stay-duration exclusion criterion) and the sepsis-definition comparison (Table 5: GRU AUROC varies from 79.2 to 89.2) provide clear, quantitative evidence that task-definition decisions can swamp model-class differences. This directly validates the paper's central motivation.

- **First reported baselines for the AUMC dataset.** Tables 2 and 3 provide the first benchmark results on this Dutch ICU dataset across five tasks, expanding the geographic diversity of available clinical ML benchmarks.

- **Demonstrates transfer learning value.** Fine-tuning an eICU model on HiRID (Figure 3) outperforms training from scratch, especially with <4,000 target samples — a concrete demonstration of the unified data format's practical utility.

---

## Weaknesses

### Fatal
None.

### Major
None. The framework is sound, the experiments are competently run, and the limitations are honestly stated.

### Minor

- **Hyperparameter tuning protocol risks slight optimism in performance estimates.** Tuning uses 2/3 of folds (≈3 of 5), then final evaluation uses all 5 folds. The 2 held-out folds provide unbiased estimates, but the 3 folds used for tuning also contribute to the final validation numbers, potentially introducing mild optimism. This does not undermine the framework's value — absolute numbers should simply be taken as indicative rather than definitive. (Section 4.1, lines 221–225)

- **No calibration results reported despite the framework supporting them.** The paper states calibration curves are recorded (line 176) but reports only AUROC/AUPRC/MAE. For clinically relevant tasks like mortality prediction, calibration is arguably as important as discrimination; this is a missed opportunity to demonstrate a clinically meaningful dimension of the framework's capabilities.

- **No discussion of class imbalance handling.** For sepsis prediction, the paper notes ~1% prevalence (line 313) but does not state whether models used balanced loss weights, oversampling, or threshold optimization. For a benchmark where prevalence varies substantially across tasks and datasets (e.g., sepsis AUPRCs often <0.10), clarity on this point would be informative.

### Trivial
None.

---

## Nice-to-Haves

- **Quantitative decomposition of performance variance.** A simple analysis (e.g., what fraction of total performance variance is explained by dataset vs. model class vs. task definition) would sharpen the paper's main interpretative claim beyond the existing qualitative-but-quantified comparisons.

- **Calibration metrics for at least one task.** Reporting Brier score or expected calibration error for mortality prediction would increase clinical relevance without adding a new experiment.

- **Clinical context for the 52-feature set.** The paper pragmatically chose features available across all datasets. Noting which clinical scoring systems (e.g., SOFA, qSOFA, KDIGO) these features cover would increase clinical confidence.

---

## Removed Points

These points are flagged to be removed; treat them with caution.

1. **"The claim that dataset/cohort/preprocessing matters more than model class is supported only by qualitative observation."** This is factually inaccurate. The paper provides exact AUROC numbers showing cohort-criteria changes shift performance by 2–3 points (Table 3) and sepsis-definition changes shift performance by up to 10 points (Table 5), while model-class differences within a cohort are typically <1% (Table 2). The evidence is quantitative. The reviewer's request for a formal variance decomposition is a reasonable suggestion for strengthening, not a correction of a missing analysis.

2. **"No statistical significance tests across model comparisons."** The paper emboldens results within one standard deviation of the best (Table 2 caption), which is a standard and transparent heuristic for benchmark comparisons. Formal significance tests (e.g., Wilcoxon signed-rank across folds) would add marginal value for a framework paper that does not stake a claim about model superiority.

3. **"The paper does not discuss class imbalance handling beyond noting prevalence."** Moved to Minor — see Weaknesses section.

4. **"The choice of 52 features is not justified clinically."** Moved to Nice-to-Haves. The paper's rationale ("already implemented in all datasets") is a practical necessity for cross-dataset harmonization and is transparently stated.

---

## Novel Insights

The most valuable insight from the reviews — one that goes beyond the paper's own explicit claims — is that YAIB's value does **not** (and should not) depend on the absolute precision of its baseline numbers. The hyperparameter-tuning concern and the lack of calibration results would be more serious for a leaderboard-style benchmark claiming state-of-the-art results. But YAIB is a *framework* first and a *benchmark* second; its primary contribution is enabling reproducible, configurable, multi-dataset experiments. The specific numbers in Tables 2–3 are demonstrations of the pipeline, not competitive claims. The reviews collectively reinforce that the paper's contribution is architectural (how comparisons can be made) rather than factual (what the best model is).

---

## Suggestions

1. **Acknowledge the mild optimism from the tuning protocol explicitly** in a "Limitations" paragraph, noting that the 2 held-out folds provide unbiased estimates while the 3 tuning folds may carry some optimism, and that future users should treat absolute numbers as indicative.

2. **Include Brier score or expected calibration error** for the mortality task (framework already records these) in an appendix or supplement.

3. **State the class imbalance handling strategy** (or lack thereof) — even a short sentence noting whether models used default loss functions or balanced weighting would suffice.

---

## Score and Decision

**Originality:** 7 — YAIB fills a genuine gap (multi-dataset extensible ICU benchmark) but builds on existing harmonization tools (ricu) and benchmark designs. The combination is novel, not each component individually.

**Importance of research question:** 8 — Reproducibility and comparability in clinical ML is an urgent problem, and the paper addresses it directly.

**Claims well-supported:** 7 — The main claim (cohort/definition choices matter more than model class) is supported by quantitative evidence. Minor methodological caveats exist but do not threaten the conclusion.

**Soundness of experiments:** 7 — Competently executed across 4 datasets, 5 tasks, 6 models. The tuning protocol concern is the main blemish.

**Clarity of writing:** 8 — Well-structured, motivation is clear, contributions are explicitly stated.

**Value to the community:** 8 — Provides a practical tool with immediate utility for clinical ML researchers. The demo datasets (no credentialing needed) are a particular strength.

**Overall:** This is a solid contribution that addresses a real need. The weaknesses are minor and do not undermine the framework's utility or the paper's main findings.

MY FINAL SCORE: <pineapple>7.5</pineapple>
MY FINAL DECISION: <orange>Accept</orange>